Basic Principles of Bone Cell Biology

Translational Endocrinology of Bone

Volumn , Issue , 2013, Pages 5-26

  Martin, T John ^a,b   Wah Ng, Kong ^a,b   Sims, Natalie A ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882756427     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415784-2.00002-6     Document Type: Chapter

References (225)

1. Civitelli R. Cell-cell communication in the osteoblast/osteocyte lineage. Arch Biochem Biophys 2008 May 15, 473(2):188-192.
2. Peck W.A., Birge S.J., Fedak S.A. Bone cells: biochemical and biological studies after enzymatic isolation. Science 1964 Dec 11, 146:1476-1477.
3. Luben R.A., Wong G.L., Cohn D.V. Biochemical characterization with parathormone and calcitonin of isolated bone cells: provisional identification of osteoclasts and osteoblasts. Endocrinology 1976 Aug, 99(2):526-534.
4. Partridge N.C., Alcorn D., Michelangeli V.P., Ryan G., Martin T.J. Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res 1983 Sep, 43(9):4308-4314.
5. Majeska R.J., Rodan S.B., Rodan G.A. Parathyroid hormone-responsive clonal cell lines from rat osteosarcoma. Endocrinology 1980 Nov, 107(5):1494-1503.
6. Crawford A., Atkins D., Martin T.J. Rat osteogenic sarcoma cells: comparison of the effects of prostaglandins E1, E2, I2 (prostacyclin), 6-keto F1alpha and thromboxane B2 on cyclic AMP production and adenylate cyclase activity. Biochem Biophys Res Commun 1978 Jun 29, 82(4):1195-1201.
7. Partridge N.C., Alcorn D., Michelangeli V.P., Kemp B.E., Ryan G.B., Martin T.J. Functional properties of hormonally responsive cultured normal and malignant rat osteoblastic cells. Endocrinology 1981 Jan, 108(1):213-219.
8. Partridge N.C., Kemp B.E., Livesey S.A., Martin T.J. Activity ratio measurements reflect intracellular activation of adenosine 3′,5′-monophosphate-dependent protein kinase in osteoblasts. Endocrinology 1982 Jul, 111(1):178-183.
9. Sudo H., Kodama H.A., Amagai Y., Yamamoto S., Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 1983 Jan, 96(1):191-198.
10. Allan E.H., Ho P.W., Umezawa A., Hata J., Makishima F., Gillespie M.T., et al. Differentiation potential of a mouse bone marrow stromal cell line. J Cell Biochem 2003 Sep 1, 90(1):158-169.
11. Stein G.S., Lian J.B., Gerstenfeld L.G., Shalhoub V., Aronow M., Owen T., et al. The onset and progression of osteoblast differentiation is functionally related to cellular proliferation. Connect Tissue Res 1989, 20(1-4):3-13.
12. Bianco P., Robey P.G., Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008 Apr 10, 2(4):313-319.
13. Bianco P., Robey P.G., Saggio I., Riminucci M. "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease. Hum Gene Ther 2010 Sep, 21(9):1057-1066.
14. Friedenstein A.J. Precursor cells of mechanocytes. Int Rev Cytol 1976, 47:327-359.
15. Bab I., Ashton B.A., Syftestad G.T., Owen M.E. Assessment of an in vivo diffusion chamber method as a quantitative assay for osteogenesis. Calcif Tissue Int 1984 Jan, 36(1):77-82.
16. Friedenstein A.J., Latzinik N.V., Gorskaya U.F., Sidorovich S.Y. Radiosensitivity and postirradiation changes of bone marrow clonogenic stromal mechanocytes. Int J Radiat Biol Relat Stud Phys Chem Med 1981 May, 39(5):537-546.
17. Friedenstein A.J. Osteogenic stem cells. Bone and Mineral Research 1990, 243-272. Elsevier, Amsterdam. J.N.M. Heerschje, J.A. Kanis (Eds.).
18. Lundberg P., Allison S.J., Lee N.J., Baldock P.A., Brouard N., Rost S., et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem 2007 Jun 29, 282(26):19082-19091.
19. Kalajzic I., Staal A., Yang W.P., Wu Y., Johnson S.E., Feyen J.H., et al. Expression profile of osteoblast lineage at defined stages of differentiation. J Biol Chem 2005 Jul 1, 280(26):24618-24626.
20. Paic F., Igwe J.C., Nori R., Kronenberg M.S., Franceschetti T., Harrington P., et al. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone 2009 Oct, 45(4):682-692.
21. Modder U.I., Khosla S. Skeletal stem/osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodeling compartment. J Cell Biochem 2008 Feb 1, 103(2):393-400.
22. Otsuru S., Tamai K., Yamazaki T., Yoshikawa H., Kaneda Y. Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells 2008 Jan, 26(1):223-234.
23. Doherty M.J., Ashton B.A., Walsh S., Beresford J.N., Grant M.E., Canfield A.E. Vascular pericytes express osteogenic potential in vitro and in vivo. J Bone Miner Res 1998 May, 13(5):828-838.
24. Kalajzic Z., Li H., Wang L.P., Jiang X., Lamothe K., Adams D.J., et al. Use of an alpha-smooth muscle actin GFP reporter to identify an osteoprogenitor population. Bone 2008 Sep, 43(3):501-510.
25. Dellavalle A., Sampaolesi M., Tonlorenzi R., Tagliafico E., Sacchetti B., Perani L., et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 2007 Mar, 9(3):255-267.
26. Fujisaki J., Wu J., Carlson A.L., Silberstein L., Putheti P., Larocca R., et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 2011 Jun 9, 474(7350):216-219.
27. Simmons P.J., Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991 Jul 1, 78(1):55-62.
28. Gronthos S., Zannettino A.C., Graves S.E., Ohta S., Hay S.J., Simmons P.J. Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J Bone Miner Res 1999 Jan, 14(1):47-56.
29. Stewart K., Walsh S., Screen J., Jefferiss C.M., Chainey J., Jordan G.R., et al. Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J Bone Miner Res 1999 Aug, 14(8):1345-1356.
30. Aubin J.E. Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2001 Jan, 2(1):81-94.
31. Aubin J.E. Advances in the osteoblast lineage. Biochem Cell Biol 1998, 76(6):899-910.
32. Stein G.S., Lian J.B. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 1993 Aug, 14(4):424-442.
33. Karsenty G. Minireview: transcriptional control of osteoblast differentiation. Endocrinology 2001 Jul, 142(7):2731-2733.
34. Karsenty G., Kronenberg H.M., Settembre C. Genetic control of bone formation. Annu Rev Cell Dev Biol 2009, 25:629-648.
35. Ducy P., Starbuck M., Priemel M., Shen J., Pinero G., Geoffroy V., et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999 Apr 15, 13(8):1025-1036.
36. Thirunavukkarasu K., Miles R.R., Halladay D.L., Yang X., Galvin R.J., Chandrasekhar S., et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 2001 Sep 28, 276(39):36241-36250.
37. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002 Jan 11, 108(1):17-29.
38. Yang X., Matsuda K., Bialek P., Jacquot S., Masuoka H.C., Schinke T., et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry syndrome. Cell 2004 Apr 30, 117(3):387-398.
39. Sabatakos G., Sims N.A., Chen J., Aoki K., Kelz M.B., Amling M., et al. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 2000 Sep, 6(9):985-990.
40. Shirakabe K., Terasawa K., Miyama K., Shibuya H., Nishida E. Regulation of the activity of the transcription factor Runx2 by two homeobox proteins, Msx2 and Dlx5. Genes Cells 2001 Oct, 6(10):851-856.
41. el Ghouzzi V., Le Merrer M., Perrin-Schmitt F., Lajeunie E., Benit P., Renier D., et al. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 1997 Jan, 15(1):42-46.
42. Howard T.D., Paznekas W.A., Green E.D., Chiang L.C., Ma N., Ortiz de Luna R.I., et al. Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 1997 Jan, 15(1):36-41.
43. Gutierrez S., Javed A., Tennant D.K., van Rees M., Montecino M., Stein G.S., et al. CCAAT/enhancer-binding proteins (C/EBP) beta and delta activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. J Biol Chem 2002 Jan 11, 277(2):1316-1323.
44. Wu M., Hesse E., Morvan F., Zhang J.P., Correa D., Rowe G.C., et al. Zfp521 antagonizes Runx2, delays osteoblast differentiation in vitro, and promotes bone formation in vivo. Bone 2009 Apr, 44(4):528-536.
45. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999 Oct, 4(4):585-595.
46. Tanaka T., Yoshida N., Kishimoto T., Akira S. Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J 1997 Dec 15, 16(24):7432-7443.
47. Quach J.M., Walker E.C., Allan E., Solano M., Yokoyama A., Kato S., et al. Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment. J Biol Chem 2011 Feb 11, 286(6):4186-4198.
48. Justesen J., Stenderup K., Ebbesen E.N., Mosekilde L., Steiniche T., Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001, 2(3):165-171.
49. Martin R.B., Chow B.D., Lucas P.A. Bone marrow fat content in relation to bone remodeling and serum chemistry in intact and ovariectomized dogs. Calcif Tissue Int 1990 Mar, 46(3):189-194.
50. Ahdjoudj S., Lasmoles F., Holy X., Zerath E., Marie P.J. Transforming growth factor beta2 inhibits adipocyte differentiation induced by skeletal unloading in rat bone marrow stroma. J Bone Miner Res 2002 Apr, 17(4):668-677.
51. Walker E., McGregor N., Poulton I., Pompolo S., Allan E., Quinn J., et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res 2008 Dec, 23:2025-2032.
52. Walker E.C., McGregor N.E., Poulton I.J., Solano M., Pompolo S., Fernandes T.J., et al. Oncostatin M promotes bone formation independently of resorption through the leukemia inhibitory factor receptor. J Clin Invest 2010, in press.
53. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002 May 16, 346(20):1513-1521.
54. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001 Nov 16, 107(4):513-523.
55. Rawadi G., Vayssiere B., Dunn F., Baron R., Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003 Oct, 18(10):1842-1853.
56. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass D.A., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002 Apr 15, 157(2):303-314.
57. Babij P., Zhao W., Small C., Kharode Y., Yaworsky P.J., Bouxsein M.L., et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003 Jun, 18(6):960-974.
58. Glass D.A., Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology 2007 Jun, 148(6):2630-2634.
59. Morvan F., Boulukos K., Clement-Lacroix P., Roman Roman S., Suc-Royer I., Vayssiere B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006 Jun, 21(6):934-945.
60. Kulkarni N.H., Onyia J.E., Zeng Q., Tian X., Liu M., Halladay D.L., et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006 Jun, 21(6):910-920.
61. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005 May, 8(5):751-764.
62. Kramer I., Halleux C., Keller H., Pegurri M., Gooi J.H., Weber P.B., et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010 Jun, 30(12):3071-3085.
63. Kubota T., Michigami T., Sakaguchi N., Kokubu C., Suzuki A., Namba N., et al. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd. J Bone Miner Res 2008 Oct, 23(10):1661-1671.
64. Holmen S.L., Zylstra C.R., Mukherjee A., Sigler R.E., Faugere M.C., Bouxsein M.L., et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005 Jun 3, 280(22):21162-21168.
65. Yadav V.K., Ryu J.H., Suda N., Tanaka K.F., Gingrich J.A., Schutz G., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008 Nov 28, 135(5):825-837.
66. Yadav V.K., Balaji S., Suresh P.S., Liu X.S., Lu X., Li Z., et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 2010 Mar, 16(3):308-312.
67. Inose H., Zhou B., Yadav V.K., Guo X.E., Karsenty G., Ducy P. Efficacy of serotonin inhibition in mouse models of bone loss. J Bone Miner Res 2011 Sep, 26(9):2002-2011.
68. Cui Y., Niziolek P.J., MacDonald B.T., Zylstra C.R., Alenina N., Robinson D.R., et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011 Jun, 17(6):684-691.
69. Bonewald L.F. The amazing osteocyte. J Bone Miner Res 2011 Feb, 26(2):229-238.
70. Holmbeck K., Bianco P., Pidoux I., Inoue S., Billinghurst R.C., Wu W., et al. The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J Cell Sci 2005 Jan 1, 118(Pt 1):147-156.
71. Wetterwald A., Hoffstetter W., Cecchini M.G., Lanske B., Wagner C., Fleisch H., et al. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 1996 Feb, 18(2):125-132.
72. Loots G.G., Kneissel M., Keller H., Baptist M., Chang J., Collette N.M., et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005 Jul, 15(7):928-935.
73. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002 Feb, 39(2):91-97.
74. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001 Mar 1, 10(5):537-543.
75. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009 Apr, 24(4):578-588.
76. Eddleston A., Marenzana M., Moore A.R., Stephens P., Muzylak M., Marshall D., et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009 Oct, 24(10):1662-1671.
77. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011 Jan, 26(1):19-26.
78. van Bezooijen R.L., ten Dijke P., Papapoulos S.E., Lowik C.W. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005 Jun, 16(3):319-327.
79. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005 Aug, 37(2):148-158.
80. Genetos D.C., Yellowley C.E., Loots G.G. Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression. PLoS ONE 2011, 6(3):e17772.
81. Genetos D.C., Toupadakis C.A., Raheja L.F., Wong A., Papanicolaou S.E., Fyhrie D.P., et al. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem 2010 May 15, 110(2):457-467.
82. Powell W.F., Barry K.J., Tulum I., Kobayashi T., Harris S.E., Bringhurst F.R., et al. Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol 2011 Apr, 209(1):21-32.
83. Schipani E., Lanske B., Hunzelman J., Luz A., Kovacs C.S., Lee K., et al. Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescues mice that lack parathyroid hormone-related peptide. Proc Natl Acad Sci USA 1997 Dec 9, 94(25):13689-13694.
84. de Souza R.L., Pitsillides A.A., Lanyon L.E., Skerry T.M., Chenu C. Sympathetic nervous system does not mediate the load-induced cortical new bone formation. J Bone Miner Res 2005 Dec, 20(12):2159-2168.
85. Sawakami K., Robling A.G., Ai M., Pitner N.D., Liu D., Warden S.J., et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 2006 Aug 18, 281(33):23698-23711.
86. Robling A.G., Bellido T., Turner C.H. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 2006 Oct-Dec, 6(4):354.
87. Moustafa A., Sugiyama T., Prasad J., Zaman G., Gross T.S., Lanyon L.E., et al. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int 2011 May 15.
88. Tatsumi S., Ishii K., Amizuka N., Li M., Kobayashi T., Kohno K., et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007 Jun, 5(6):464-475.
89. Gaudio A., Pennisi P., Bratengeier C., Torrisi V., Lindner B., Mangiafico R.A., et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010 May, 95(5):2248-2253.
90. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009 Oct, 24(10):1651-1661.
91. Tian X., Jee W.S., Li X., Paszty C., Ke H.Z. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2011 Feb, 48(2):197-201.
92. Papanicolaou S.E., Phipps R.J., Fyhrie D.P., Genetos D.C. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 2009, 46(5):389-399.
93. Niikura T., Hak D.J., Reddi A.H. Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures. J Orthop Res 2006 Jul, 24(7):1463-1471.
94. Hak D.J., Makino T., Niikura T., Hazelwood S.J., Curtiss S., Reddi A.H. Recombinant human BMP-7 effectively prevents non-union in both young and old rats. J Orthop Res 2006 Jan, 24(1):11-20.
95. Mantila Roosa S.M., Liu Y., Turner C.H. Gene expression patterns in bone following mechanical loading. J Bone Miner Res 2011 Jan, 26(1):100-112.
96. Heller-Steinberg M. Ground substance, bone salts, and cellular activity in bone formation and destruction. Am J Anat 1951 Nov, 89(3):347-379.
97. Belanger L.F., Robichon J. Parathormone-induced osteolysis in dogs. a microradiographic and alpharadiographic survey. J Bone Joint Surg Am 1964 Jul, 46:1008-1012.
98. Belanger L.F. Osteocytic osteolysis. Calcif Tissue Res 1969 Aug 11, 4(1):1-12.
99. Teti A., Zallone A. Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone 2009 Jan, 44(1):11-16.
100. Boyde A. Evidence against osteocytic osteolysis. Bone Histomorphometry Third International Workshop 1980, Societe Nouvelle de Publications Medicales et Dentaires, Paris. W.S.S. Jee, A.M. Parfitt (Eds.).
101. Holtrop M.E., King G.J., Cox K.A., Reit B. Time-related changes in the ultrastructure of osteoclasts after injection of parathyroid hormone in young rats. Calcif Tissue Int 1979 Apr 17, 27(2):129-135.
102. Parfitt A.M. The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption-bone flow theory. Clin Orthop Relat Res 1977, (127):236-247.
103. Qing H., Ardeshirpor L., Dusevich V., Wysolmerski J., Bonewald L.F. Osteocyte perilacunar remodeling is regulated hormonally, but not by mechanical unloading. J Bone Min Res 2009, 29(Suppl 1):S440.
104. Bonewald L. The holy grail of high bone mass. Nat Med 2011 Jun, 17(6):657-658.
105. Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J.Q., et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011, 17(10):1231-1234.
106. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation. Nat Med 2011, 17(10):1235-1241.
107. Kogianni G., Mann V., Noble B.S. Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. J Bone Miner Res 2008 Jun, 23(6):915-927.
108. Kolliker A. Die Normal Resorption des Knochengewebes und ihre Bedeutung die Entstehung der Typischen Knochenformen. Liepzig: Vogel FCW 1873.
109. Holtrop M.E., King G.J. The ultrastructure of the osteoclast and its functional implications. Clin Orthop Relat Res 1977 Mar-Apr, (123):177-196.
110. Vaes G. Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation, and mode of action of osteoclasts. Clin Orthop Relat Res 1988 Jun, (231):239-271.
111. Baron R. Molecular mechanisms of bone resorption: therapeutic implications. Rev Rhum Engl Ed 1996 Nov, 63(10):633-638.
112. Arnett T.R., Dempster D.W. Protons and osteoclasts. J Bone Miner Res 1990 Nov, 5(11):1099-1103.
113. Burger E.H., van der Meer J.W., Nijweide P.J. Osteoclast formation from mononuclear phagocytes: role of bone-forming cells. J Cell Biol 1984 Dec, 99(6):1901-1906.
114. Scheven B.A., Visser J.W., Nijweide P.J. In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature 1986 May 1-7, 321(6065):79-81.
115. Nicholson G.C., Moseley J.M., Sexton P.M., Mendelsohn F.A., Martin T.J. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest 1986 Aug, 78(2):355-360.
116. Tonna E.A. Osteoclasts and the aging skeleton: a cytological, cytochemical and autoradiographic study. Anat Rec 1960 Jul, 137:251-269.
117. Young R.W. Cell proliferation and specialization during endochondral osteogenesis in young rats. J Cell Biol 1962 Sep, 14:357-370.
118. Rasmussen H., Bordier P. The Physiological Basis of Metabolic Bone Disease 1974, Williams and Wilkins, Waverley Press, Baltimore.
119. Kahn A.J., Simmons D.J. Investigation of cell lineage in bone using a chimaera of chick and quial embryonic tissue. Nature 1975 Nov 27, 258(5533):325-327.
120. Nijweide P.J., Burger E.H., Feyen J.H. Cells of bone: proliferation, differentiation, and hormonal regulation. Physiol Rev 1986 Oct, 66(4):855-886.
121. Loutit J.F., Townsend K.M. Longevity of osteoclasts in radiation chimaeras of osteopetrotic beige and normal mice. Br J Exp Pathol 1982 Apr, 63(2):221-223.
122. Martin T.J., Partridge N.C., Greaves M., Atkins D., Ibbotson K.J. Prostaglandin effects on bone and role in cancer hypercalcaemia. Molecular Endocrinology 1979, 251-264. Elsevier, Amsterdam. I. MacIntyre, M. Szelke (Eds.).
123. Rodan G.A., Martin T.J. Role of osteoblasts in hormonal control of bone resorption-a hypothesis. Calcif Tissue Int 1981, 33(4):349-351.
124. Chambers T.J. cof bone resorption. Clin Orthop Relat Res 1980 Sep, (151):283-293.
125. Chambers T.J. The pathobiology of the osteoclast. J Clin Pathol 1985 Mar, 38(3):241-252.
126. Akatsu T., Takahashi N., Udagawa N., Sato K., Nagata N., Moseley J.M., et al. Parathyroid hormone (PTH)-related protein is a potent stimulator of osteoclast-like multinucleated cell formation to the same extent as PTH in mouse marrow cultures. Endocrinology 1989 Jul, 125(1):20-27.
127. Akatsu T., Takahashi N., Udagawa N., Imamura K., Yamaguchi A., Sato K., et al. Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J Bone Miner Res 1991 Feb, 6(2):183-189.
128. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993 Dec 15, 90(24):11924-11928.
129. Takahashi N., Yamana H., Yoshiki S., Roodman G.D., Mundy G.R., Jones S.J., et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988 Apr, 122(4):1373-1382.
130. Suda T., Takahashi N., Martin T.J. Modulation of osteoclast differentiation. Endocr Rev 1992 Feb, 13(1):66-80.
131. Takahashi N., Akatsu T., Udagawa N., Sasaki T., Yamaguchi A., Moseley J.M., et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988 Nov, 123(5):2600-2602.
132. Yamashita T., Asano K., Takahashi N., Akatsu T., Udagawa N., Sasaki T., et al. Cloning of an osteoblastic cell line involved in the formation of osteoclast-like cells. J Cell Physiol 1990 Dec, 145(3):587-595.
133. Udagawa N., Takahashi N., Akatsu T., Sasaki T., Yamaguchi A., Kodama H., et al. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 1989 Oct, 125(4):1805-1813.
134. Kitazawa R., Kitazawa S. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun 2002 Jan 18, 290(2):650-655.
135. Udagawa N., Takahashi N., Katagiri T., Tamura T., Wada S., Findlay D.M., et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 1995 Nov 1, 182(5):1461-1468.
136. Gao Y., Morita I., Maruo N., Kubota T., Murota S., Aso T. Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation. Bone 1998 May, 22(5):487-493.
137. Martin T.J., Ng K.W. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J Cell Biochem 1994 Nov, 56(3):357-366.
138. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 Apr 18, 89(2):309-319.
139. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997 May 8, 234(1):137-142.
140. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 Apr 17, 93(2):165-176.
141. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998 Mar 31, 95(7):3597-3602.
142. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998 May 1, 12(9):1260-1268.
143. Udagawa N., Takahashi N., Yasuda H., Mizuno A., Itoh K., Ueno Y., et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000 Sep, 141(9):3478-3484.
144. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999 Nov 18, 402(6759):304-309.
145. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999 Sep 15, 13(18):2412-2424.
146. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997 Dec 15, 186(12):2075-2080.
147. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997 Nov 13, 390(6656):175-179.
148. Horwood N.J., Kartsogiannis V., Quinn J.M., Romas E., Martin T.J., Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999 Nov, 265(1):144-150.
149. Jimi E., Akiyama S., Tsurukai T., Okahashi N., Kobayashi K., Udagawa N., et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999 Jul 1, 163(1):434-442.
150. Quinn J.M., Neale S., Fujikawa Y., McGee J.O., Athanasou N.A. Human osteoclast formation from blood monocytes, peritoneal macrophages, and bone marrow cells. Calcif Tissue Int 1998 Jun, 62(6):527-531.
151. Matsuzaki K., Udagawa N., Takahashi N., Yamaguchi K., Yasuda H., Shima N., et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998 May 8, 246(1):199-204.
152. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998 Nov, 139(11):4743-4746.
153. Lee S.K., Lorenzo J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999 Aug, 140(8):3552-3561.
154. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999 Oct, 140(10):4451-4458.
155. Lai F.P., Cole-Sinclair M., Cheng W.J., Quinn J.M., Gillespie M.T., Sentry J.W., et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004 Jul, 126(2):192-201.
156. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003 Apr, 111(8):1221-1230.
157. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999 Jun, 20(3):345-357.
158. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003 May 15, 423(6937):337-342.
159. Teitelbaum S.L., Ross F.P. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003 Aug, 4(8):638-649.
160. Hikita A., Tanaka S. Ectodomain shedding of receptor activator of NF-kappaB ligand. Adv Exp Med Biol 2007, 602:15-21.
161. Lum L., Wong B.R., Josien R., Becherer J.D., Erdjument-Bromage H., Schlondorff J., et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999 May 7, 274(19):13613-13618.
162. Lynch C.C., Hikosaka A., Acuff H.B., Martin M.D., Kawai N., Singh R.K., et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005 May, 7(5):485-496.
163. Hikita A., Yana I., Wakeyama H., Nakamura M., Kadono Y., Oshima Y., et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem 2006 Dec 1, 281(48):36846-36855.
164. Yamanaka H., Makino K., Takizawa M., Nakamura H., Fujimoto N., Moriya H., et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in rheumatoid synovium. Lab Invest 2000 May, 80(5):677-687.
165. Sabbota A.L., Kim H.R., Zhe X., Fridman R., Bonfil R.D., Cher M.L. Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 2010 Jul 1, 70(13):5558-5566.
166. Wilson T.J., Nannuru K.C., Futakuchi M., Sadanandam A., Singh R.K. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 2008 Jul 15, 68(14):5803-5811.
167. Proell V., Xu H., Schuler C., Weber K., Hofbauer L.C., Erben R.G. Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone 2009 Oct, 45(4):677-681.
168. Frost Dynamics of bone remodeling. Bone Biodyn 1964, 1964:315-333.
169. Parfitt A.M. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 1982, 4(1):1-6.
170. Eriksen E.F. Normal and pathological remodeling of human trabecular
171. Martin T.J., Gooi J.H., Sims N.A. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr 2009, 19:73-88.
172. Lips P., Courpron P., Meunier P.J. Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 1978 Nov 10, 26(1):13-17.
173. Hauge E.M., Qvesel D., Eriksen E.F., Mosekilde L., Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001 Sep, 16(9):1575-1582.
174. Fujikawa Y., Quinn J.M., Sabokbar A., McGee J.O., Athanasou N.A. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996 Sep, 137(9):4058-4060.
175. Eghbali-Fatourechi G.Z., Modder U.I., Charatcharoenwitthaya N., Sanyal A., Undale A.H., Clowes J.A., et al. Characterization of circulating osteoblast lineage cells in humans. Bone 2007 May, 40(5):1370-1377.
176. Eriksen E.F., Eghbali-Fatourechi G.Z., Khosla S. Remodeling and vascular spaces in bone. J Bone Miner Res 2007 Jan, 22(1):1-6.
177. Howson K.M., Aplin A.C., Gelati M., Alessandri G., Parati E.A., Nicosia R.F. The postnatal rat aorta contains pericyte progenitor cells that form spheroidal colonies in suspension culture. Am J Physiol Cell Physiol 2005 Dec, 289(6):C1396-C1407.
178. Matsumoto T., Kawamoto A., Kuroda R., Ishikawa M., Mifune Y., Iwasaki H., et al. Therapeutic potential of vasculogenesis and osteogenesis promoted by peripheral blood CD34-positive cells for functional bone healing. Am J Pathol 2006 Oct, 169(4):1440-1457.
179. Yamamoto Y., Udagawa N., Matsuura S., Nakamichi Y., Horiuchi H., Hosoya A., et al. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. Endocrinology 2006 Jul, 147(7):3366-3374.
180. Mizoguchi T., Muto A., Udagawa N., Arai A., Yamashita T., Hosoya A., et al. Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. J Cell Biol 2009 Feb 23, 184(4):541-554.
181. Malone J.D., Kahn A.J., Teitelbaum S.L. Dissociation of organic acid secretion from macrophage mediated bone resorption. Biochem Biophys Res Commun 1982 Sep 30, 108(2):468-473.
182. Yu X., Huang Y., Collin-Osdoby P., Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003 Aug, 18(8):1404-1418.
183. Verborgt O., Gibson G.J., Schaffler M.B. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 2000 Jan, 15(1):60-67.
184. Verborgt O., Tatton N.A., Majeska R.J., Schaffler M.B. Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation?. J Bone Miner Res 2002 May, 17(5):907-914.
185. Noble B.S., Peet N., Stevens H.Y., Brabbs A., Mosley J.R., Reilly G.C., et al. Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol 2003 Apr, 284(4):C934-C943.
186. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002 Apr 18, 416(6882):744-749.
187. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994 Oct 21, 266(5184):443-448.
188. Zhao C., Irie N., Takada Y., Shimoda K., Miyamoto T., Nishiwaki T., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006 Aug, 4(2):111-121.
189. Hughes D.E., Boyce B.F. Apoptosis in bone physiology and disease. Mol Pathol 1997 Jun, 50(3):132-137.
190. Nakamura T., Imai Y., Matsumoto T., Sato S., Takeuchi K., Igarashi K., et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007 Sep 7, 130(5):811-823.
191. Henriksen K., Gram J., Schaller S., Dahl B.H., Dziegiel M.H., Bollerslev J., et al. Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 2004 May, 164(5):1537-1545.
192. Karsdal M.A., Henriksen K., Sorensen M.G., Gram J., Schaller S., Dziegiel M.H., et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 2005 Feb, 166(2):467-476.
193. Everts V., Delaisse J.M., Korper W., Jansen D.C., Tigchelaar-Gutter W., Saftig P., et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 2002 Jan, 17(1):77-90.
194. Perez-Amodio S., Beertsen W., Everts V. (Pre-)osteoclasts induce retraction of osteoblasts before their fusion to osteoclasts. J Bone Miner Res 2004 Oct, 19(10):1722-1731.
195. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors 2004 Dec, 22(4):233-241.
196. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992 Apr 3, 69(1):11-25.
197. Mohan S., Baylink D.J. Bone growth factors. Clin Orthop Relat Res 1991 Feb, (263):30-48.
198. Hauschka P.V., Mavrakos A.E., Iafrati M.D., Doleman S.E., Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986 Sep 25, 261(27):12665-12674.
199. Critchlow M.A., Bland Y.S., Ashhurst D.E. The effects of age on the response of rabbit periosteal osteoprogenitor cells to exogenous transforming growth factor-beta 2. J Cell Sci 1994 Feb, 107(Pt 2):499-516.
200. Joyce M.E., Roberts A.B., Sporn M.B., Bolander M.E. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990 Jun, 110(6):2195-2207.
201. Bonewald L.F., Wakefield L., Oreffo R.O., Escobedo A., Twardzik D.R., Mundy G.R. Latent forms of transforming growth factor-beta (TGF beta) derived from bone cultures: identification of a naturally occurring 100-kDa complex with similarity to recombinant latent TGF beta. Mol Endocrinol 1991 Jun, 5(6):741-751.
202. Martin T.J., Allan E.H., Fukumoto S. The plasminogen activator and inhibitor system in bone remodelling. Growth Regul 1993 Dec, 3(4):209-214.
203. Tang Y., Wu X., Lei W., Pang L., Wan C., Shi Z., et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009 Jul, 15(7):757-765.
204. Wu X., Pang L., Lei W., Lu W., Li J., Li Z., et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 2010 Nov 5, 7(5):571-580.
205. Gray C., Boyde A., Jones S.J. Topographically induced bone formation in vitro: implications for bone implants and bone grafts. Bone 1996 Feb, 18(2):115-123.
206. Stains J.P., Civitelli R. Gap junctions in skeletal development and function. Biochim Biophys Acta 2005 Dec 20, 1719(1-2):69-81.
207. Dalby M.J., McCloy D., Robertson M., Agheli H., Sutherland D., Affrossman S., et al. Osteoprogenitor response to semi-ordered and random nanotopographies. Biomaterials 2006 May, 27(15):2980-2987.
208. Allan E.H., Hausler K.D., Wei T., Gooi J.H., Quinn J.M., Crimeen-Irwin B., et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 2008 Aug, 23(8):1170-1181.
209. Gale N.W., Holland S.J., Valenzuela D.M., Flenniken A., Pan L., Ryan T.E., et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996 Jul, 17(1):9-19.
210. Pasquale E.B. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005 Jun, 6(6):462-475.
211. Luiz de Freitas P.H., Li M., Ninomiya T., Nakamura M., Ubaidus S., Oda K., et al. Intermittent PTH administration stimulates pre-osteoblastic proliferation without leading to enhanced bone formation in osteoclast-less c-fos(-/-) mice. J Bone Miner Res 2009 Sep, 24(9):1586-1597.
212. Del Fattore A., Peruzzi B., Rucci N., Recchia I., Cappariello A., Longo M., et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 2006 Apr, 43(4):315-325.
213. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991 Feb 22, 64(4):693-702.
214. Kornak U., Kasper D., Bosl M.R., Kaiser E., Schweizer M., Schulz A., et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001 Jan 26, 104(2):205-215.
215. Pennypacker B., Shea M., Liu Q., Masarachia P., Saftig P., Rodan S., et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009 Feb, 44(2):199-207.
216. Chiusaroli R., Knobler H., Luxenburg C., Sanjay A., Granot-Attas S., Tiran Z., et al. Tyrosine phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo. Mol Biol Cell 2004 Jan, 15(1):234-244.
217. Lee S.H., Rho J., Jeong D., Sul J.Y., Kim T., Kim N., et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 2006 Dec, 12(12):1403-1409.
218. Sims N.A., Jenkins B.J., Quinn J.M., Nakamura A., Glatt M., Gillespie M.T., et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 2004 Feb, 113(3):379-389.
219. Martin T.J., Sims N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005 Feb, 11(2):76-81.
220. Takeuchi Y., Watanabe S., Ishii G., Takeda S., Nakayama K., Fukumoto S., et al. Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem 2002 Dec 13, 277(50):49011-49018.
221. Cornish J., Callon K., King A., Edgar S., Reid I.R. The effect of leukemia inhibitory factor on bone in vivo. Endocrinology 1993 Mar, 132(3):1359-1366.
222. Pederson L., Ruan M., Westendorf J.J., Khosla S., Oursler M.J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA 2008 Dec 30, 105(52):20764-20769.
223. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001 May 22, 98(11):6500-6505.
224. Ferron M., Wei J., Yoshizawa T., Del Fattore A., DePinho R.A., Teti A., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010 Jul 23, 142(2):296-308.
225. Oury F., Sumara G., Sumara O., Ferron M., Chang H., Smith C.E., et al. Endocrine regulation of male fertility by the skeleton. Cell 2011 Mar 4, 144(5):796-809.